Colorectal Adenoma: Clinical Trials

5 trials for Colorectal Adenoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 not yet recruiting, 1 unknown. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 3, Not yet recruiting 1, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Colorectal Adenoma: new trials by email Literature Review of Colorectal Adenoma trials Research Report on Colorectal Adenoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas
Jianpi Lishi Jiedu Granules, Placebo granules - Colorectal Adenoma
Phase 3Not yet recruitingNanjing First Hospital, Nanjing Medical University3762026-05-012026-04-01
Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence
Berberine hydrochloride, placebo - Colorectal Adenoma
Phase 2 / Phase 3CompletedShanghai Jiao Tong University School of Medicine11082014-11-012019-03-26
Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence
Ca plus vit D - Colorectal Adenoma
Phase 2 / Phase 3UnknownShanghai Jiao Tong University School of Medicine9002014-03-012014-05-21
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
Celecoxib - Colorectal Adenoma
Phase 3CompletedPfizer15612001-02-012008-08-06
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
MK0966; Rofecoxib / Duration of Treatment: 156 weeks, Placebo/ Duration of Treatment: 156 weeks - Colorectal Adenoma
Phase 3CompletedMerck Sharp & Dohme LLC25861999-12-232017-05-09

Interventions

Calcium Carbonate (1)  ·  Celecoxib (1)  ·  Duration of Therapy (1)  ·  rofecoxib (1)

Sponsors

Shanghai Jiao Tong University School of Medicine (2)  ·  Merck Sharp & Dohme LLC (1)  ·  Nanjing First Hospital, Nanjing Medical University (1)  ·  Pfizer (1)

Countries

China (3)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Israel (1)

Top investigators

Jing-Yuan Fang, M.D., Ph.D (2)

Results publications

PMID 16943394, PMID 16943401, PMID 18378608, PMID 18922570, PMID 21503000, PMID 22386831, PMID 31926918, PMID 37553874